Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
Milestone Scientific‘s today priced an upcoming offering, looking to raise approximately $3 million.
The Livingston, N.J.-based company said it plans to offer 2 million shares of common stock at $1.50. Each share sold will include warrants for the purchase of an additional 0.75 common shares of stock, offering an additional total 1.5 million shares. Read more
SMC Ltd., said today that it acquired auto-injector developer Oval Medical Technologies for an undisclosed amount. Cambridge, UK-based Oval Medical Technologies develops auto-injectors for a 2-step administration of non-viscous and viscous drugs using cyclic olefin plastic and glass primary drug containers.
Somerset, Wisconsin-based SMC is a global contract manufacturer of single-use devices for pharmaceutical, medical and diagnostics companies. Read more
StimGuard said today it enrolled the 1st patient in a clinical trial of its StimGuard miniature implantable device designed to treat urinary incontinence resulting from refractory overactive bladder syndrome.
The Fort Lauderdale, Fla.-based company’s system is implanted at the tibial nerve through a needle-sized introducer and uses wireless technology to stimulate the nerve and treat the symptoms of overactive bladder. Read more
Sanovas said yesterday it launched another subsidiary, SteriView, along with its SteriView instrument inspection and infection control system.
The newly launched system is designed as a “front line solution” against hospital-acquired infections, Sausalito, Calif.-based Sanovas said. The system allows direct visual inspection and cleaning of hard to reach spaces on endoscopes and medical instruments. Read more
EnteroMedics today released a real-world assessment of weight loss data from patients using its Maestro vBloc therapy device and associated programs, touting between 9% and 10% total weight loss at 6 and 9 months, respectively.
St. Paul, Minn.-based EnteroMedic’s Maestro device is an implantable neurostimulation device designed to intermittently block the vagus nerves using high-frequency, low-energy impulses. The therapy, which the company calls “vBloc,” is approved in the U.S., Europe and Australia to aid in weight loss in obese adults with a body mass index of 40 to 45 or a related health condition and a BMI of 35 to 39.9. Read more